Beta Bionics now carries an updated fair value estimate of US$23.80 per share, up from about US$21.67, which refines how ...
Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” ...
Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint ...
Zacks Investment Research on MSN
Beta Bionics stock down despite iLet-Eversense 365 integration deal
Beta Bionics, Inc. BBNX recently announced a partnership with Senseonics SENS to expand compatibility between its automated ...
Beta Bionics stock fell about 72% from $31.99 to under $9 as investors sued over alleged FDA-related misstatements on its ...
IRVINE, Calif., November 13, 2024 (Newswire.com) - Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announces the successful closing of a $60 ...
The average one-year price target for Beta Bionics (NASDAQGM:BBNX) has been revised to $23.75 / share. This is an increase of 14.64% from the prior estimate of $20.72 dated September 11, 2026. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results